Aloxistatin

Aloxistatin

SCHEMBL21981208

CCOC(=O)C1OC1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CAPN1 P07384 15/20 1.00
▸ CTSL P07711 3/20 1.00
▸ CTSB P07858 3/20 1.00
▸ LMNA P02545 1/20 1.00
▸ CTSG P08311 1/20 1.00
▸ CAPN9 O14815 3/20 0.72
▸ MAPK1 P28482 2/20 0.72
▸ CTSH P09668 1/20 0.49
▸ CTSS P25774 1/20 0.49
▸ CTSK P43235 1/20 0.49
▸ CTSC P53634 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aloxistatin SCHEMBL18498407 1.00 CAPN1 (1.00) CAPN1CTSLCTSBLMNACTSG
Aloxistatin SCHEMBL21981210 1.00 CAPN1 (1.00) CAPN1CTSLCTSBLMNACTSG
Aloxistatin SCHEMBL12620387 1.00 CAPN1 (1.00) CAPN1CTSLCTSBLMNACTSG
Aloxistatin SCHEMBL254426 1.00 CAPN1 (1.00) CAPN1CTSLCTSBLMNACTSG
Aloxistatin SCHEMBL483320 1.00 CAPN1 (1.00) CAPN1CTSLCTSBLMNACTSG
SCHEMBL22273610 0.93 CAPN1 (0.87) CAPN1CTSLCTSBLMNACTSG
Aloxistatin SCHEMBL9314220 0.93 CAPN1 (0.86) CAPN1CTSLCTSBLMNACTSG
SCHEMBL12653616 0.91 CAPN1 (0.83) CAPN1CTSLCTSBLMNACTSG
SCHEMBL12653864 0.91 CAPN1 (0.83) CAPN1CTSLCTSBLMNACTSG
SCHEMBL1804811 0.91 CAPN1 (0.83) CAPN1CTSLCTSBLMNACTSG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200165608-A1 INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS NATIONAL SCIENCE FOUNDATION 2020-05-28 — — US disclosed
Send feedback